UID:
almafu_9961565541602883
Format:
1 online resource
Edition:
Third edition.
ISBN:
1-9751-7926-9
,
1-9751-7925-0
Note:
Includes index.
,
Intro -- Title Page -- Copyright Page -- Contributors -- Preface -- Acknowledgments -- Contents -- SECTION 1 Targets by Organ Site -- Color Key -- Abbreviations -- Adrenocortical Carcinoma (ACC)-Mouhammed A. Habra, Aung Naing -- Agnostic to Tumor Site-Gerald S. Falchook -- Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct, Cholangiocarcinoma)-Goldy C. George, David S. Hong, Milind Javle, Kathrina Marcelo-Lewis, Ahmed O. Kaseb -- Bladder Carcinoma (Urothelial Cancer)-Arlene O. Siefker-Radtke -- Brain Tumors-Michael Pearlman, Vivek Subbiah Glioblastoma/Malignant Gliomas -- Other NF-Related Tumors -- Medulloblastoma -- Meningiomas -- Breast Cancer-Senthil Damodaran, Debu Tripathy ER/PR+ -- HER2+ -- Triple-Negative/Basal -- Cervical Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Colorectal Cancer-David S. Hong, E. Scott Kopetz, Allan A. L. Pereira -- Esophageal Cancer (Squamous Cell)-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Gastric/Gastroesophageal Junction Adenocarcinoma-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Head and Neck Cancer-Renata Ferrarotto, Sangeeta Goswami, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Erminia Massarelli Salivary Gland -- Squamous Cell -- Nasopharynx -- Kidney (Renal Cell) Cancer-Vivek Subbiah, Nizar M. Tannir -- Leukemia-Prajwal C. Boddu, Tapan M. Kadia, Radhika Kainthla, Naveen Pemmaraju Acute Myeloid Leukemia (AML) -- Acute Lymphoblastic Leukemia (ALL) -- Chronic Myeloid Leukemia (CML) -- Chronic Lymphocytic Leukemia (CLL) -- Myeloproliferative Neoplasm (MPN) -- Liver Cancer (Hepatocellular)-Ahmed O. Kaseb, Xiaochun Liu, Shiraj Sen -- Lung Cancer-Niamh Coleman, Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner NSCLC -- SCLC -- Lymphoma-Maliha Khan, Xiaochun Liu, Raphael Steiner, Jason R. Westin.
,
Multiple Myeloma-Manojkumar Bupathi, Gregory Kaufman, Robert Orlowski -- Ovarian Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Pancreatic Cancer (Ductal Carcinoma)-Goldy C. George, Milind Javle, Kathrina Marcelo-Lewis, Shubham Pant -- Prostate Cancer (Adenocarcinoma)-Patrick Pilie -- Sarcoma-Anthony Conley, David S. Hong, Jason Roszik, Vivek Subbiah Gastrointestinal Stromal Tumors, GIST -- Sarcoma -- Skin Cancer-Gerald S. Falchook, Meredith A. McKean, Michael K. K. Wong, Scott E. Woodman Melanoma -- Basal Cell -- Squamous Cell -- Merkel Cell -- Small Bowel Cancer-Gerald S. Falchook -- Testicular Cancer (Germ Cell Carcinoma)-Lance C. Pagliaro, Vivek Subbiah -- Thymus Carcinoma (Thymic and Thymoma)-Gerald S. Falchook, Ralph G. Zinner -- Thyroid Cancer-Manojkumar Bupathi, Maria E. Cabanillas, Gerald S. Falchook Papillary and Follicular Carcinoma -- Papillary, Follicular, and Hurthle Cell Carcinoma -- Medullary Carcinoma -- Anaplastic Carcinoma -- Uterine (Endometrial) Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- SECTION 2 Carcinogenesis from the Perspective of Targeted Therapy and Immunotherapy -- SECTION 3 Molecular Targets and Pathways -- An Introduction to the Organization of Cancer Cell Signaling -- Signal Transduction Roadmap -- VEGF and VEGFR -- FGF and FGFR -- PDGF and PDGFR -- Angiopoietin and TIE Receptors -- IGFR and Insulin Receptors -- Targeting IGFR and Insulin Receptors -- TGFβ/SMAD -- EGFR -- EGFR Signaling -- HER2 (Also Known as ERBB2) -- MET (Also Known as HGF Receptor) -- RET Receptor -- ALK Receptor -- KIT Receptor -- ROS Receptor -- Receptor Tyrosine Kinases (Activation Cascade) -- Cell Signaling Pathways Rapamycin and Its Mammalian Target (mTOR) -- PI3K-AKT-mTOR Pathway -- PI3K, AKT, PTEN, TSC in Cancer -- mTORC1,2 -- NF-Kappa B-Master Immune Regulator -- NF-κB Pathway -- G-Protein-Coupled Receptors.
,
Mitogen-Activated Protein Kinase (MAPK) -- RAS/MAPK Pathway -- Targeting BRAF/MEK -- Rous Sarcoma Virus Oncogene (SRC) -- SRC Pathway -- β-Catenin-Cell Adhesion -- Wnt Pathway -- Fruit Fly Mutations and Related Genes -- Hedgehog Pathway -- NOTCH Pathway -- B-Cell Lymphoma 2 (BCL-2)/Cysteine Aspartates (CASPASES) -- Janus Kinase and Signal Transducer and Transcription -- JAK/STAT Pathway -- Apoptosis (Greek-"Leaves Falling from a Tree") -- Death Receptors (DRs) and Apoptosis -- Nuclear Factors and DNA Repair -- TP53: Master Cell Cycle Regulator -- Cell Regulation by RB1, CDKs -- DNA Damage Response -- Aurora Kinase -- Overview of Angiogenic Signaling -- Angiogenesis: A Hallmark of Cancer -- Angiogenesis Regulators -- Immunotherapy -- Management of Immune-Related Adverse Events (irAEs) -- Epigenetics -- Targeting Epigenetics -- Antibody Drug Conjugates (ADCs) Have Variable "Payloads" and Multiple Microenvironmental Targets -- Tropomyosin-Related Kinases -- Metabolism: Glycolysis and the TCA Cycle -- Targeting Cancer Metabolism -- Ewing Sarcoma Gene Fusion -- SECTION 4 Targeted and Immunotherapy Agents -- Color Key -- Abbreviations -- Abemaciclib -- Abiraterone Acetate -- Acalabrutinib -- Acalisib -- Adavosertib -- Ado-Trastuzumab Emtansine -- Afatinib Dimaleate -- Afuresertib -- Alectinib -- Alemtuzumab (Campath-1H) -- Alisertib -- All-Trans Retinoic Acid (ATRA) -- Alpelisib -- Alrizomadlin -- Altiratinib -- AMG337 -- Amivantamab-vmjw -- Anastrozole -- Andecaliximab (GS-5745) -- Anetumab Ravtansine -- Anlotinib -- Apalutamide -- Apatinib -- Atezolizumab -- Avapritinib -- Avelumab -- Axicabtagene Ciloleucel -- Axitinib -- Belagenpumatucel-L -- Belantamab Mafodotin -- Belinostat -- Belizatinib -- Bemarituzumab -- Bempegaldesleukin -- Berzosertib -- Bevacizumab -- BI 811283 -- Bicalutamide -- Binimetinib -- Bintrafusp Alfa -- Blinatumomab -- BMS-936559.
,
Bortezomib -- Bosutinib -- Brentuximab Vedotin -- Brexucabtagene Autoleucel -- Brigatinib -- Brivanib Alaninate -- Bryostatin 1 -- Buparlisib -- Cabozantinib -- Camrelizumab -- Capivasertib -- Capmatinib -- Carfilzomib -- Cediranib Maleate -- Cemiplimab -- Ceritinib -- Cetuximab -- Cevostamab -- Ciltacabtagene Autoleucel -- Cixutumumab -- Cobimetinib Fumarate -- Copanlisib -- Crenolanib Besylate -- Crizotinib -- Dabrafenib -- Dacomitinib -- Dactolisib -- Danvatirsen -- Daratumumab -- Darolutamide -- Darovasertib -- Dasatinib -- Debio-1347 -- Demcizumab -- Dostarlimab -- Double Antiangiogenic Protein -- Dovitinib -- Durvalumab -- Duvelisib -- Elotuzumab -- Enasidenib Mesylate -- Encorafenib -- Enfortumab Vedotin -- Ensartinib -- Entrectinib -- Enzalutamide -- Enzastaurin -- Epratuzumab -- Erdafitinib -- Erlotinib -- Everolimus -- Farletuzumab -- Ficlatuzumab -- Figitumumab -- Foretinib -- Fostamatinib Disodium -- Fulvestrant -- Futibatinib -- Galunisertib -- Ganitumab -- Gefitinib -- Geldanamycin -- Gemtuzumab Ozogamicin -- Gilteritinib Fumarate -- Glasdegib Maleate -- Ibrutinib -- Icotinib -- Idecabtagene Vicleucel -- Idelalisib -- Imatinib Mesylate -- Imifoplatin397 -- Iniparib -- Inotuzumab Ozogamicin -- Ipafricept -- Ipatasertib -- Ipilimumab -- Isatuximab -- Ivosidenib -- Lanreotide -- Lapatinib Ditosylate -- Larotrectinib -- Lenalidomide -- Lenvatinib Mesylate -- LGK974 -- Linifanib -- Linsitinib -- Loncastuximab Tesirine -- Lorlatinib -- Lucitanib -- Lurbinectedin -- Lutetium Lu 177 Dotatate -- Margetuximab-cmkb -- Matuzumab -- Midostaurin -- Milademetan -- Miransertib -- Mirvetuximab Soravtansine -- MK-0752 -- MK-2206 -- MK-8242 -- MKC-1 -- Mocetinostat -- Mogamulizumab-kpkc -- Momelotinib -- nab-Rapamycin -- Napabucasin -- Naquotinib Mesylate -- Navitoclax -- Nazartinib -- Necitumumab -- Neratinib -- Nilotinib -- Nintedanib -- Niraparib.
,
Nirogacestat -- Nivolumab -- Obatoclax Mesylate -- Obinutuzumab -- Ofatumumab -- Olaparib -- Olaratumab -- Olmutinib -- Onartuzumab -- Onatasertib -- Osimertinib -- Pacritinib -- Palbociclib -- Panitumumab -- Panobinostat -- Parsaclisib -- Pazopanib Hydrochloride -- Pelareorep -- Pembrolizumab -- Pemetrexed -- Pemigatinib -- Peposertib -- Perifosine -- Pertuzumab -- Pexidartinib -- Pilaralisib -- Pimasertib -- Pomalidomide -- Ponatinib Hydrochloride -- Poziotinib -- Pralatrexate -- Pralsetinib -- Prexasertib -- Pyrotinib -- Quizartinib -- Ramucirumab -- Razuprotafib -- RC48-ADC -- Rebastinib -- Refametinib -- Regorafenib -- Ridaforolimus -- Rigosertib -- Rilotumumab -- Ripretinib -- Rituximab -- Romidepsin -- Rovalpituzumab Tesirine -- Rucaparib Camsylate -- Ruxolitinib Phosphate -- Sacituzumab Govitecan -- Sapanisertib -- Saracatinib -- Selinexor -- Selitrectinib -- Selpercatinib -- Selumetinib -- Serabelisib -- Sintilimab -- Sipuleucel-T -- Sirolimus -- Sitravatinib -- Sonidegib -- Sonolisib -- Sorafenib -- Sotatercept -- Sotorasib -- Spartalizumab -- Sunitinib -- TAK580 -- Taladegib -- Talazoparib Tosylate -- Taletrectinib -- Talimogene Laherparepvec -- Talquetamab -- Tazemetostat Hydrobromide -- Teclistamab -- Telaglenastat -- Telatinib -- Temsirolimus -- Tepotinib -- Thalidomide -- Tipifarnib -- Tirabrutinib -- Tisagenlecleucel -- Tisotumab Vedotin-tftv -- Tivantinib -- Toripalimab -- Trabectedin -- Trabedersen -- Trametinib -- Trastuzumab -- Trebananib -- Tremelimumab -- Tucatinib -- Ulixertinib -- Uprosertib -- Urelumab -- Vadastuximab Talirine -- Valproic Acid -- Vandetanib -- Vanucizumab -- Vatalanib -- Veliparib -- Vemurafenib -- Venetoclax -- Vevorisertib -- Vismodegib -- Vistusertib -- Vocimagene Amiretrorepvec -- Vopratelimab -- Vorinostat -- Xentuzumab -- Zalutumumab -- Zanidatamab -- Zanubrutinib -- Ziv-Aflibercept -- Zotatifin.
,
Index.
Additional Edition:
ISBN 1-9751-7924-2
Language:
English
Bookmarklink